Hwankyu Kang

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis

Kévin Pethe, Pablo Bifani, Jichan Jang et al. · Nature Medicine · 2013 · 595 citations · Full text

Medicinal Chemistry, Potent Clinical Candidate, Pulmonary Tuberculosis +7

Lead Optimization of a Novel Series of Imidazo[1,2-<i>a</i>]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

Sun‐Hee Kang, Ryang Yeo Kim, Min Jung Seo et al. · Journal of Medicinal Chemistry · 2014 · 173 citations · Full text

Pharmaceutical Science, Bioorganic Chemistry, Extensively-drug-resistant Anti-tuberculosis Agent +18

Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects

Jeongjun Kim, Jin‐Ho Choi, Hwankyu Kang et al. · Antimicrobial Agents and Chemotherapy · 2021 · 37 citations · Full text

A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment

Yeejin Jeon, Hwankyu Kang, Yeongin Yang et al. · Cancers · 2022 · 17 citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +15

Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial

Jeongjun Kim, Jin‐Ho Choi, Hwankyu Kang et al. · Antimicrobial Agents and Chemotherapy · 2022 · 15 citations · Full text